Compared to ERI alone, treatment with ERI plus SXN had a greater effective rate than ER alone (odds ratio = 3.94; 95% CI: 2.85, 5.44; I2 = 0%, P < .00001), a lower National Institute of Health Stroke Scale (SMD= −1.39; 95% CI: −1.73, −1.05; I2 = 71%, P < .00001), lower neural function defect score (SMD= −0.75; 95% CI: −1.06,−0.43; I2 = 67%, P < .00001), and lower level of neuron-specific enolase (SMD= −2.10; 95% CI: −2.85, −1.35; I2 = 85%, P < .00001). This evidence concerns the gene ENO2 and stroke disorder.